HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 148 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Colposcopia: Cómo prepararse y qué saber August 6, 2020 ESMO Calls for Cancer to Remain a Flagship Priority in the... November 5, 2025 FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... April 19, 2024 Lack of Evidence for the Use of Telemedicine in the Prevention... September 13, 2021 Load more HOT NEWS High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab
